The Italy dental care market is projected to grow from $861 Mn in 2022 to $1,362 Mn in 2030 with a CAGR of 5.9% for the year 2022-2030. Technological advancements such as 3D printing for diagnoses and robotic technologies for prostheses are future drivers for the Italy dental care market.
Australia home healthcare market is projected to grow from $4.35 Bn in 2022 to $8.94 Bn in 2030 with a CAGR of 9.43% for the year 2022-2030. The market has witnessed significant growth post-pandemic. The market is segmented by product, service, software, and by region.
Lung cancer is the fifth most common type of cancer affecting the Australian population, therefore the Australia lung cancer drugs market is projected to grow during the forecast period. The market is segmented by type, treatment, end user, route of administration, and distribution channel.
Australia Over The Counter (OTC) drugs market is projected to grow from $2.04 Bn in 2022 to $3.95 Bn in 2030 with a CAGR of 8.6% for the year 2022-2030. Major OTC innovation trends include treatment based, lifestyle based, format based and extended offering. The market is segmented by drug type and by distribution channel.
Australia Primary Hyperoxaluria (PH) market stood at around $2.1 Mn in 2022 and is projected to reach $8.8 Mn with a CAGR of 19% for the year 2022-2030. The market is segmented by type, diagnosis, drug, treatment and by distribution channel. Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are some of the key players in the Australia PH market.
Australia Sickle Cell Disease market is expected to grow from $1.1 Mn in 2022 to $2.6 Mn in 2030 with a CAGR of 11% for the year 2022 to 2030. The market is segmented by treatment modality and by distribution channel. Novartis and AstraZeneca are some of the key players in the Australia sickle cell disease market.
Brazil telemedicine market is projected to grow from $1.52 Bn in 2022 to $6.19 Bn in 2030 with a CAGR of 19.2% for the year 2022-2030. Brazil is a country with unique opportunities for the growth of telemedicine and hence will augment the growth of the telemedicine market. Cisco and GE Healthcare are the key players in the market.
The legalization of medical cannabis in Canada has resulted in the growth of Canada cannabis for GI diseases market. Cannabis can be used to treat irritable bowel disease, inflammatory bowel diseases, and colitis. The market is segmented by application and by product type.
Canada dermatology market is projected to grow from $2.78 Bn in 2022 to $5.31 Bn in 2030 with a CAGR of 8.44% for the year 2022-2030. More Canadians investing in skincare solutions is driving the Canada dermatology market. Major dermatological disorders in Canada are alopecia and psoriasis.
The Canada pharmacy market is expected to witness growth from $83.08 Bn in 2022 to $141.69 Bn in 2030 with a CAGR of 6.9% for the year 2022-2030. Major market drivers include increasing health expenditure and a rise in per capita disposable income. The market is segmented by industry products and services and by pharmacy groups.
With the advent of advanced technologies like machine learning, artificial intelligence, and Internet of things in Canada, the Canada telemedicine market is expected to grow from $4.86 Bn in 2022 to $18.53 Bn in 2030 with a CAGR of 18.2% for year 2022-2030. The market is segmented by products and services, end user, and by delivery mode.
The China antiepileptics drugs market stood at around $0.82 Bn in 2022 and is projected to reach $1.32 Bn in 2030 with a CAGR of 2.3% for the year 2022-2030. Valproic acid and Lamotrigine are the top selling antiepileptic drugs in China. The market is segmented by generation and by distribution channel.